BACKGROUND Synchronous resection of primary pancreatic ductal adenocarcinoma (PDAC) and liver metastases in highly selective patients is being accepted based on oncology research progress showing safe surgical outcomes with low morbidity and mortality. We also tried to determine patients who would benefit from the operation. METHODS From January 2012 to October 2017, 48 patients who underwent synchronous resection of primary PDAC and liver metastases were retrospectively evaluated. Twenty-three of them underwent oligometastatic synchronous resection. RESULTS The majority of synchronous resection PDAC patients underwent hepatic wedge resection, and no oligometastatic patient was treated with hemihepatectomy. The median overall survival (OS) of the synchronous resection patients was 7.8 months. Hepatic oligometastatic PDAC patients had a longer OS than that of non-oligometastatic synchronous resection patients, systemic chemotherapy patients and palliative patients (16.1 vs 6.4 months, P = 0.02; 16.1 vs 7.6 months, P = 0.02; 16.1 vs 4.3 months, P < 0.0001; respectively). Further analysis showed that localized pancreatic body/tail PDAC had a better OS in oligometastatic patients than in non-oligometastatic synchronous resection patients (16.8 months vs 7.05 months, P = 0.0004) and systemic chemotherapy patients (16.8 months vs 8 months, P = 0.003). CONCLUSION Patients with pancreatic body/tail PDAC with liver oligometastases can benefit from synchronous resection.

中文翻译：

---

肝性低转移性胰腺体/尾部导管腺癌患者可受益于同步切除术。

背景技术根据肿瘤学研究进展显示同步手术切除高选择性患者的原发性胰腺导管腺癌（PDAC）和肝转移已被接受，该研究显示出具有低发病率和低死亡率的安全手术结局。我们还试图确定将从手术中受益的患者。方法回顾性分析2012年1月至2017年10月同期行原发PDAC和肝转移的48例患者的临床资料。其中的23例行了转移性同步切除。结果大多数同步切除的PDAC患者均接受了肝楔形切除术，并且未接受过半肝切除的少转移患者。同步切除患者的中位总生存期（OS）为7.8个月。肝低转移PDAC患者的OS较非低转移同步切除患者，全身化疗患者和姑息患者的OS长（16.1 vs 6.4个月，P = 0.02; 16.1 vs 7.6个月，P = 0.02; 16.1 vs 4.3个月，P < 0.0001；分别）。进一步的分析表明，与非非转移同步切除患者（16.8个月vs 7.05个月，P = 0.0004）和全身化疗患者（16.8个月vs 8个月，P = 0.003）相比，局部转移的胰体/尾PDAC的OS更好。 ）。结论胰体/尾PDAC伴有肝低聚转移的患者可从同步切除术中受益。P = 0.02；16.1 vs 4.3个月，P <0.0001；分别）。进一步的分析表明，与非非转移同步切除患者（16.8个月vs 7.05个月，P = 0.0004）和全身化疗患者（16.8个月vs 8个月，P = 0.003）相比，局部转移的胰体/尾PDAC的OS更好。 ）。结论胰体/尾PDAC伴有肝低聚转移的患者可从同步切除术中受益。P = 0.02；16.1 vs 4.3个月，P <0.0001；分别）。进一步的分析表明，与非非转移同步切除患者（16.8个月vs 7.05个月，P = 0.0004）和全身化疗患者（16.8个月vs 8个月，P = 0.003）相比，局部转移的胰体/尾PDAC的OS更好。 ）。结论胰体/尾PDAC伴有肝低聚转移的患者可从同步切除术中受益。